Skip to main content
Cell & Gene

Manufacturing CGTs: Should I Use A CDMO?

September 30, 2022
Authors
Deeona R. GaskinRaj D. Pai

Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).

Click here to view the article.

Contacts

Gaskin, Deeona R.
合伙人律师
Pai, Raj D.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

Navigating the European Health Data Space Regulation: An (Uneasy) Marriage Between EHDS and GDPR (April 2026, Part 2)April 14, 2026
GoodLifeSci
Sidley Recognized in Legal 500 EMEA 2026March 25, 2026
荣誉
Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026
GoodLifeSci
EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 19, 2025
GoodLifeSci
Sidley Lawyer Michael Borden To Speak on “The Biosecure Act: What Chinese Biotech and Life Sciences Companies Need To Know” WebinarThursday, December 18, 2025
活动
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025
GoodLifeSci